{
    "clinical_study": {
        "@rank": "109207", 
        "arm_group": [
            {
                "arm_group_label": "LIK066 2.5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 2.5 mg of LIK066 once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "LIK066 5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 5 mg of LIK066 once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "LIK066 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 10 mg of LIK066 once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "LIK066 25 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 25 mg of LIK066 once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "LIK066 50 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 50 mg of LIK066 once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "LIK066 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 100 mg of LIK066 once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "LIK066 150 mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 150 mg of LIK066 once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive 100 mg sitagliptin once daily for 12 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive placebo for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy, tolerability and short-term safety of\n      LIK066 to support dose selection for phase 3."
        }, 
        "brief_title": "Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Confirmed diagnosis of T2DM by standard criteria\n\n          2. Drug-na\u00efve patients, defined as patients not having received any anti-diabetic\n             medication previously,\n\n          3. Currently untreated patients , who, after the diagnosis of T2DM, have received\n             anti-diabetic medication for not more than 12 consecutive weeks, and have not\n             received any anti-diabetic treatment within 12 weeks prior to Visit 1\n\n          4. Patients being treated with  mono-therapy for at least 8 consecutive weeks prior to\n             Visit 1 with the following OADs: metformin, dipeptidyl peptidase-4 inhibitors\n             (DPP-4i), SU, glinide, alpha-glucosidase inhibitor (AGI)\n\n          5. HbA1c \u2265 7 to \u2264 10.5%  at Visit 1 for drug-na\u00efve/currently untreated patients\n\n          6. HbA1c \u2265 7 to \u2264 9.5%  at Visit 1 for patients treated with OAD monotherapy\n\n          7. HbA1c \u2265 7 to \u2264 10.5%  at Visit 199 for ALL patients\n\n          8. Age: \u226518 and \u2264 75 years old at Visit 1\n\n          9. BMI \u226522 to \u226445 kg/m2 at Visit 1\n\n        Exclusion Criteria:\n\n          1. FPG \u2265270 mg/dl (15 mmol/L) for drug-na\u00efve/currently untreated patients or \u2265240 mg/dl\n             (13.3 mmol/L) for patients on OAD monotherapy at Visit 1\n\n          2. Insulin treatment >4 consecutive weeks in the last 6 months, corticosteroid use >7\n             days in the last 8 weeks, use of growth hormones in the last 6 months, or use of\n             weight control products > 4 weeks in the last 6 months\n\n          3. History of acute metabolic complications, CV disease, type 1 diabetes mellitus,\n             hepatic disorders, pancreatitis, chronic diarrhea\n\n          4. Significant lab abnormalities such as TSH outside of normal range, UACR>300 mg/g\n             creatinine, eGFR <60 ml/min/1.73m2, hemoglobin <12 g/L in men and <11 g/L in women,\n             hematuria\n\n          5. ECG abnormalities including AV block, long QT syndrome or QTc>450 msec for men and\n             >470 msec for women\n\n          6. History of malignancy\n\n          7. Women of child-bearing potential not using effective methods of contraception Other\n             protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01824264", 
            "org_study_id": "CLIK066A2202", 
            "secondary_id": "2012-005793-63"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LIK066 2.5 mg", 
                    "LIK066 5 mg", 
                    "LIK066 10 mg", 
                    "LIK066 25 mg", 
                    "LIK066 50 mg", 
                    "LIK066 100 mg", 
                    "LIK066 150 mg"
                ], 
                "description": "Experimental treatment doses", 
                "intervention_name": "LIK066", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg", 
                "description": "Active comparator treatment dose", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo comparator dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sitagliptin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Type 2 Diabetes mellitus, SGLT inhibitors, dose-response", 
        "lastchanged_date": "April 2, 2014", 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Canada", 
                "Guatemala", 
                "Hungary", 
                "Italy", 
                "Mexico", 
                "Poland", 
                "Portugal", 
                "Russian Federation", 
                "Slovakia", 
                "South Africa", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "9", 
        "official_title": "A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Evaluate Change in HbA1c After 12 Weeks Monotherapy With 7 Doses of LIK066 Compared With Placebo or Sitagliptin in Patients With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in HbA1c after 12 weeks of treatment in each of the LIK066 doses and placebo", 
            "measure": "Change from baseline in glycated hemoglobin (HbA1c) after 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "baseline, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01824264"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The effect of LIK066 on fasting plasma glucose after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in Fasting Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on urinary glucose to creatinine ratio after 12 weeks of treatment will be evaluated", 
                "measure": "Change from baseline in urinary glucose to creatinine ratio", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on change in body weight after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in Body weight", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on change in systolic and diastolic blood pressure after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on change in postprandial glucose during a meal test after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in postprandial glucose during a meal test", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on change in beta cell function during a meal test after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in beta cell function during a meal test", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066on change in insulin secretion relative to glucose during a meal test after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in insulin secretion relative to glucose during a meal test", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on change in oral glucose insulin sensitivity during a meal test after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in oral glucose insulin sensitivity during a meal test", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on change in glucagon-like peptide during a meal test after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in glucagon-like peptide response during a meal test", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on change in peptide YY response during a meal test after 12 weeks of treatment will be evaluated.", 
                "measure": "Change from baseline in Peptide YY response during a meal test", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }, 
            {
                "description": "The safety and tolerability of 7 doses of LIK066  after 12 weeks of treatment will be evaluated with number of patients reported for total adverse events, serious adverse events and death.", 
                "measure": "Number of patients with adverse events to assess safety and tolerability of LIK066", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The effect of LIK066 on renal threshold for glucose excretion will be calculated from glucose values in an overnight urine collection", 
                "measure": "Change from baseline in renal threshold for glucose excretion", 
                "safety_issue": "No", 
                "time_frame": "baseline, 12 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2015", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}